Company Overview#
MannKind Corporation recently shared its earnings report for the first quarter of 2026, showcasing a 15% increase in revenue compared to the same period last year. The company generated $90 million in revenue, largely due to the addition of FUROSCIX sales following its acquisition of scPharmaceuticals. Despite this growth, MannKind reported a non-GAAP net loss of $0.02 per share, which was worse than the expected loss of $0.01 per share.
Key Financial Highlights#
- Total Revenue: $90 million, a 15% increase year-over-year.
- FUROSCIX Sales: $15.5 million, marking a new revenue source after the acquisition.
- Afrezza Sales: $15.3 million, a slight increase of 3% from the previous year.
- Collaboration & Services Revenue: $23.5 million, down 20% from last year.
- Royalty Revenue: $32.7 million, up 9% year-over-year.
- Non-GAAP Net Loss: $6.9 million or $0.02 per share.
Earnings vs. Expectations#
MannKind's earnings per share of -$0.02 fell short of the anticipated -$0.01, resulting in a negative surprise of 100%. The total revenue of $90 million also missed the forecast of $107.53 million by 16.12%. This discrepancy highlights the challenges the company faced during the integration of its recent acquisitions and shifts in marketing strategy.
Market Response#
Despite the earnings miss, MannKind's stock experienced a significant surge of 18.88% in aftermarket trading, closing at $3.40. This increase may reflect investor optimism regarding the company's future growth potential, driven by new product launches and strategic acquisitions. The stock has shown resilience, moving up from its previous close of $2.86, and remains within its 52-week trading range of $2.23 to $6.51.